Skip to content
    BCDA
    Earnings call· Jun 2026(Q2 FY26)

    BioCardia Q2 FY26 earnings call BCDA

    Aug 12, 2026 Source

    Executive summary

    BioCardia Q2 FY26 — Regulatory Progress and Japan Market Opportunity

    BioCardia reported significant regulatory progress in Q2 FY26, particularly with positive interactions with Japanese and US authorities for its cardiac cell therapy and delivery catheter. The company is preparing for a Shonin submission in Japan next quarter, which could open a substantial market, and continues to advance its confirmatory US trial while addressing FDA feedback. Financial results showed reduced net losses and extended cash runway, supported by ATM facility utilization.

    Highlights

    5
    • Received positive consultation record from Japan's PMDA supporting Shonin pre-market regulatory submission for cardiac cell therapy, with submission expected next quarter.

    • FDA confirmed the ongoing Cardi-Amp Heart Failure II trial may support premarket approval, viewing it as a confirmatory trial.

    • FDA agreed on two pathways for Helix marketing clearance and raised no safety concerns for the Helix Transcendental Cardio Delivery Catheter System.

    • Secured net proceeds of approximately $4.9 million under ATM facility at an average price of $1.22 per share, providing cash runway into 2027.

    • Net loss decreased to $1.6 million in Q2 FY26 from $2.0 million in Q2 FY25, and to $3.9 million for the six months ended June 2026 from $4.9 million in the prior year period.

    Concerns

    4
    • PMDA requested additional details on guideline-directed medical therapy compliance and all-cause death/transplantation/LVAD implantation for the CAR-D-AMP trials.

    • Formal meeting minutes from FDA regarding Helix de novo pre-submission, expected June 12th, are still pending.

    • Enrollment in the CAR-D-AMP Heart Failure II trial is not at "blazing speeds" due to resource deployment and focus on PMDA submission.

    • The third tier of the composite outcome (quality of life) in the Cardi-Amp Heart Failure II trial has faced criticism in the scientific community, requiring further discussion with FDA.

    Guidance & targets

    3
    CategoryTargetConfidence
    PMDA regulatory submission
    Shonin regulatory submission for cardiac cell therapy
    high materiality
    High
    Japan approval timeline
    Approximately 12 months after Shonin submission
    high materiality
    Medium
    Cash runway
    Into 2027
    medium materiality
    High

    Operational metrics

    23
    Cash used in operations
    $1.7 millionincreased slightly from $1.6 million in Q2 FY25
    Q2 FY26

    Cash used in operations during the three months ended June 2026.

    Net cash used in operations
    $3.4 millionincreased slightly from $3.3 million in 6 months ended June 2025
    6 months ended June 2026

    Net cash used in operations for the six months ended June 2026, primarily due to timing of supplier payments.

    Net proceeds from ATM facility
    $4.9 million
    Q2 FY26

    Funds raised under the at-the-market facility, which has a lower cost of capital and does not involve dilutive securities like warrants.

    Cash and cash equivalents balance
    $5.4 million
    Q2 FY26

    Balance at the end of the quarter, providing runway into 2027.

    Equity balance
    $2.7 million
    Q2 FY26

    Equity balance at the end of the quarter, believed to keep the company compliant with NASDAQ listing standards.

    Total expense decrease
    $0.4 millionvs $2.1 million in Q2 FY25
    Q2 FY26

    Total expense decreased quarter over quarter to $1.6 million in Q2 FY26.

    Total expense decrease
    $0.9 millionvs $4.8 million in 6 months ended June 2025
    6 months ended June 2026

    Total expense decreased for the six months ended June 2026 to $3.9 million.

    R&D expense decrease
    $0.5 millionvs $1.4 million in Q2 FY25
    Q2 FY26

    Research and development expense decreased to $0.9 million in Q2 FY26, primarily due to the closeout of the CAR-D-AMP heart failure trial.

    R&D expense decrease
    $0.8 millionvs $2.9 million in 6 months ended June 2025
    6 months ended June 2026

    Research and development expense decreased to $2.1 million for the six months ended June 2026.

    SG&A expense
    $0.7 millionconsistent quarter over quarter
    Q2 FY26

    Selling general and administrative expenses remained consistent.

    SG&A expense
    $1.8 milliondecreased slightly from $1.9 million in 6 months ended June 2025
    6 months ended June 2026

    Selling general and administrative expenses for the six-month period.

    Net loss
    $1.6 millionvs $2.0 million in Q2 FY25
    Q2 FY26

    Net loss for the second quarter of 2026.

    Net loss
    $3.9 millionvs $4.9 million in 6 months ended June 2025
    6 months ended June 2026

    Net loss for the six-month period ended June 2026.

    Peer market capitalization
    $250 million
    Q2 FY26

    Market capitalization of two publicly traded peer companies in Japan advancing cardiac cell therapies. BioCardia has performed more than 20 times as many clinical procedures as both combined.

    Competitor cell therapy reimbursement
    $326,000per treatment
    July 2026

    Reimbursement amount approved for another cell therapy for the same indication in Japan.

    Localized distributor fee
    10%
    ongoing

    Percentage of total product value taken by localized distributors in Japan, even for direct sales.

    Initial target patient population
    20,000
    initial approval

    Expected patient population for the initial indication of cardiac cell therapy in Japan.

    Total ischemic heart failure patients
    300,000
    current

    Total number of patients in Japan with ischemic heart failure today.

    Cardiac catheterization interventions
    250,000
    per year

    Number of cardiac catheterization interventions performed annually by interventional cardiologists in Japan.

    Competitor historical patients treated
    8
    historically

    Number of patients historically treated by a competitor (ReHeart) with their cell therapy.

    Cardi-AMP HF2 active clinical sites
    4
    Q2 FY26

    Number of clinical sites actively enrolling patients in the Cardi-Amp Heart Failure II trial.

    Cardi-AMP HF2 patients expected to qualify
    3
    this month

    Additional patients expected to qualify for the Cardi-Amp Heart Failure II study this month.

    Cardi-AMP HF2 patients scheduled for procedures
    2
    this month

    Patients scheduled for procedures in the Cardi-Amp Heart Failure II study this month.

    Risks & headwinds

    4
    PMDA information requestsPrior to Shonin submission (next quarter)

    8-9 patients for GDM compliance, additional details for each incidence of all-cause death, heart transplantation, or LVAD implantation

    Mitigation: BioCardia believes these requests will be addressed to PMDA satisfaction; data is being collected for the few outstanding items. Preparing formal CDISC data proactively.

    Delayed FDA minutes for Helix CatheterOngoing

    Formal meeting minutes expected June 12th are still pending

    Mitigation: Received email confirmation from FDA that confirms understanding and minutes will be sent soon. BioCardia believes it has clarity on the de novo submission nuances.

    Slow enrollment in Cardi-Amp Heart Failure II trialOngoing

    Enrollment not at 'blazing speeds'

    Mitigation: Actively onboarding additional centers; clinical team is also focused on PMDA submission. Planning to streamline the trial and seek FDA guidance on endpoint to enhance enrollment.

    Criticism of Quality of Life (QoL) endpoint in Cardi-Amp Heart Failure II trialOngoing discussions with FDA

    Third tier of composite outcome (QoL) has had a lot of criticism in the scientific community

    Mitigation: Engaging with FDA to get guidance on how to specify the use of that endpoint within the primary outcome measure. FDA has pushed back on the criticism.

    What to watch in Q3 FY26

    5

    PMDA Shonin Submission

    next quarter
    CurrentPreparing for submission
    TargetSubmission completed

    Why it matters

    Completion of this submission is a major milestone for market entry in Japan and validates the therapy.

    BioCard is preparing for the Shonin regulatory submission in Japan next quarter.

    Q&A highlights

    6

    What are the key outstanding points regarding the pending FDA minutes for the Helix de novo pre-submission, and what are the nuances of this approval pathway?

    The key outstanding point is clarity on the nuances for the de novo submission for Helix, specifically FDA's confirmation of the submission path. The FDA faces challenges approving a delivery system for a biologic without an already approved therapeutic for that indication/route. BioCardia believes its extensive data and experience for Helix, which has been used in ~500 patients and was previously CE marked, will support approval, potentially making it the first transendocardial biotherapeutic delivery catheter approved via de novo. While a de novo approval enables others to reference it, BioCardia expects its performance data to remain a significant barrier to entry.

    The key issue with FDA is they have a very challenging time approving a delivery system for a biologic for a clinical indication and a route of administration for which no therapeutic has yet been approved.

    asked by Joseph Pantginis · answered by Peter Altman

    3 min read5 chapters

    Detailed Narrative

    01

    Japan Regulatory Progress and Market Opportunity

    BioCardia received a positive consultation record from Japan's PMDA, supporting the advancement of a Shonin pre-market regulatory submission for its cardiac cell therapy. The PMDA found positive outcomes from the CAR-D-AMP trials credible but requested additional details on guideline-directed medical therapy compliance and specific adverse events. BioCardia is preparing for submission next quarter, including completing the electronic trial master file and conducting GCP audits. The initial indication in Japan is expected to target approximately 20,000 patients, with approval anticipated 12 months post-submission. The company notes a competitor's cell therapy for the same indication was approved and reimbursed at $326,000 per treatment, underscoring the market need and potential for strong pricing.

    02

    US Regulatory Interactions for Cardi-Amp Heart Failure II and Helix Catheter

    The FDA's Center for Biologics Evaluation and Research confirmed that the ongoing Cardi-Amp Heart Failure II trial may support premarket approval, viewing it as a confirmatory study. The agency had no safety or delivery concerns. BioCardia is actively enrolling patients, with four clinical sites recruiting and additional centers being onboarded. Separately, the FDA agreed on two pathways for marketing clearance of the Helix Transcendental Cardio Delivery Catheter System, raising no concerns on safety or performance. The preferred route is simultaneous approval with the cell therapy, but a de novo pathway is also suggested. The company is awaiting formal minutes from this meeting.

    03

    Financial Performance and Capital Management

    BioCardia reported a decrease in total expenses by $0.4 million quarter-over-quarter to $1.6 million in Q2 FY26, and by $0.9 million to $3.9 million for the six months ended June 2026. This was primarily driven by a reduction in R&D expense due to the closeout of the CAR-D-AMP heart failure trial. The net loss for Q2 FY26 was $1.6 million, down from $2.0 million in Q2 FY25. The company raised approximately $4.9 million in net proceeds through its ATM facility at an average price of $1.22 per share, ending the quarter with $5.4 million in cash and cash equivalents, providing a runway into 2027 and maintaining NASDAQ compliance with $2.7 million in equity.

    04

    Business Development and Future Programs

    BioCardia is engaged in active business development conversations in the Asia Pacific region for its cardiovascular therapeutics. The company expects any potential deal to include funding to advance Cardi-AMP for its second indication (chronic myocardial ischemia) and its allogeneic cardi-allo cell therapy for inflammatory heart failure. Business development for biotherapeutic delivery systems, particularly for gene-based therapy, is also active. The company is also working with CarTech to bring heart 3D fusion imaging to the clinic and market.

    05

    Cardi-Amp Heart Failure II Trial Enrollment and Endpoint Nuances

    Enrollment in the Cardi-Amp Heart Failure II trial is progressing, with four active sites and additional patients expected to qualify and undergo procedures this month. The company is actively onboarding more centers to accelerate enrollment. Discussions with the FDA are ongoing regarding the outcome measures, specifically the third tier of the composite outcome, quality of life, which has received scientific criticism. BioCardia plans to streamline the trial to focus on the primary outcome measure and seek FDA guidance on handling this endpoint.

    AI-generated summary of the company’s earnings call. Not investment advice.